Pay in 4 interest-free payments of $7.47 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
April 29 Product: X4 Pharmaceuticals Xolremdi Indication: WHIM Syndrome The FDA approved X4 Pharmaceuticals Xolremdi Monday as the first targeted treatment for WHIM syndrome, an ultra-rare immunodeficiency disease named for its four characteristics: warts, hypogammaglobulinemia, infections and myelokathexis
This differs substantially from compounds like BPC-157 and TB-500 where weight-based calculations are standard practice
Was there randomisation, blinding and a control group
Patients recovering from surgery or injury, or those wanting to reduce downtime after aesthetic skin treatments such as laser resurfacing
US$ 23.12
US$ 23.56
US$ 28.86
US$ 25.60
US$ 21.05
US$ 29.07
US$ 28.76
